Arun Rangnath Jagdale

Title: Arun Rangnath Jagdale: Innovator in PARP Inhibitor Technology

Introduction

Arun Rangnath Jagdale, based in Pune, India, is an accomplished inventor known for his significant contribution to the field of cancer treatment through innovative pharmaceutical compounds. With one patent to his name, his work focuses on developing derivatives that inhibit the PARP enzyme, a crucial target in cancer therapy.

Latest Patents

Jagdale's patent, titled "Tetrahydroquinazolinone derivatives as PARP inhibitors," discloses various compounds represented by the formula (I), along with their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts. The invention details pharmaceutical compositions that include these compounds, which can be used for treating or preventing diseases or disorders, including cancer, that respond to PARP inhibition. This groundbreaking work showcases the potential of these derivatives in modern medicine.

Career Highlights

Arun Rangnath Jagdale is currently associated with Lupin, Inc., where he focuses on research and development of novel pharmaceutical solutions. His expertise in medicinal chemistry and drug development has made him a valuable asset to his organization and the field at large.

Collaborations

Throughout his career, Jagdale has collaborated with talented professionals, including Gourhari Jana and Sanjay Pralhad Kurhade. Their collective expertise enhances the innovation capabilities within their projects, aiming for advancements in treatment protocols.

Conclusion

With his patent on Tetrahydroquinazolinone derivatives, Arun Rangnath Jagdale exemplifies the spirit of innovation within the pharmaceutical industry. His contributions not only signify personal achievement but also open new avenues for effective cancer treatment, reflecting the importance of inventive minds in advancing medical science.